Electrophysiologic and hemodynamic effects of slow-channel blocking drugs.
D000818:Animals; D001283:Atrioventricular Node / Q000502:physiology; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D003326:Coronary Circulation; D003327:Coronary Disease / Q000188:drug therapy; D004110:Diltiazem / Q000494:pharmacology; D004285:Dogs; D004594:Electrophysiology; D005260:Female; D006321:Heart / Q000187:drug effects; D006339:Heart Rate; D006352:Heart Ventricles / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008564:Membrane Potentials; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy; D009206:Myocardium / Q000166:cytology; D009543:Nifedipine / Q000494:pharmacology; D010210:Papillary Muscles / Q000166:cytology; D011690:Purkinje Fibers / Q000187:drug effects; D012804:Sick Sinus Syndrome / Q000188:drug therapy; D012849:Sinoatrial Node / Q000502:physiology; D014700:Verapamil / Q000008:administration & dosage / Q000494:pharmacology
D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine